



Pressrelease  
Lund, Sweden 2017-11-16

## **CLS receives additional order from University of Texas Medical Branch in the US**

Clinical Laserthermia Systems (CLS) (publ), has, through its subsidiary CLS Americas Inc., received yet another order for the company's single use accessories for MR-guided laser ablation from the University of Texas Medical Branch (UTMB). The order value amounts to about 100 000 SEK.

In October CLS announced that the company had signed a supplier agreement with UTMB. The agreement means that CLS is an approved supplier to UTMB, which is a prerequisite for the company when delivering equipment to the hospital. As the agreement was signed UTMB placed a first order for CLS' single use accessories for MR-guided laser ablation. UTMB has now placed an additional order.

- Dr. Eric Walser at UTMB has treated some more patients and he is pleased with the product that we have delivered. It is very positive that we now get our first repeat order for CLS' single use accessories for MR-guided laser ablation. This indicates that we have a product offer that is interesting to the market, said Dan Mogren, CCO at CLS.

CLS and UTMB signed a Letter of Intent in August 2016, aiming to establish the use of the TRANBERG® products for MR-guided laser ablation as part of standard treatment for cancer patients.

Read more about University of Texas Medical Branch: [www.utmb.edu](http://www.utmb.edu)

*This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 16 November 2017, at 11:00 AM.*

### **Company contact:**

Lars-Erik Eriksson, CEO Clinical Laserthermia Systems AB (publ)

Tel: +46 – (0)702 – 90 33 00 E-mail: [lee@clinicallaser.se](mailto:lee@clinicallaser.se)

*Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Boston, MA, USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on [www.clinicallaser.se](http://www.clinicallaser.se)*